What the business is, and whether it's a good one at a fair price.
Sells vitamins, minerals and supplements in India under brands like Neurobion (B-vitamin / nerve care), Evion (Vitamin E / muscle health), Livogen (iron), and Polybion, distributed mainly through pharmacies and increasingly through e-pharmacy platforms. The portfolio is concentrated in nerve care, muscle health and iron deficiency, with recent launches in gummy and cream formats such as Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream. Distribution runs on a super-distributor go-to-market model that has expanded Neurobion's pharmacy reach by 1.4x in five years, adding roughly 100,000 new stores. Exports contributed ₹50 crore (+12% YoY) with the Sri Lanka business growing 30%+. The business is asset-light (capex 1.1% of revenue), with materials being the largest cost at 21.8% of revenue, followed by employee costs at 15.8% and other operating expenses at 25.8%, and it generated operating cash flow of ₹338 crore in FY26.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from PROCTER & GAMBLE HEALTH L's filed financials and exchange disclosures
PROCTER & GAMBLE HEALTH L is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol PGHL.
Yes. Over the trailing twelve months PROCTER & GAMBLE HEALTH L reported a net profit of ₹357 Cr on revenue of ₹1,433 Cr.
Yes. The dividend yield is 3.80% at the current price. It paid out 104% of its profit as dividend in FY26.
Effectively yes. It holds ₹177 Cr more cash than debt. Debt stands at 0.00× equity.
On trailing P/E, PROCTER & GAMBLE HEALTH L ranks 73 of 169 in Pharmaceuticals — cheaper than 57% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session PROCTER & GAMBLE HEALTH L moves 0.82% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by PROCTER & GAMBLE HEALTH L appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
